- PackSize
- 50ug/100ug
- Target
- CD159
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Humanized
- Isotype
- IgG4-kappa
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A
- Species
- --
- Gene ID-1
- P26715
- Uniprot
- --
- Background
- Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --